Literature DB >> 15357152

Has the epidemiology of nosocomial candidemia changed?

Laura Puzniak1, Steven Teutsch, William Powderly, Louis Polish.   

Abstract

OBJECTIVE: To assess changes in the epidemiology of nosocomial candidemia in the post-fluconazole era among hospitalized patients using a case-control study design.
DESIGN: Candidemia case-patients were matched 1:1 on diagnosis, age, and length of stay with control-patients. Conditional logistic regression was used to determine predictors and outcomes of candidemia. Treatment regimens and compliance with national practice guidelines were compared among case-patients.
SETTING: Barnes-Jewish Hospital, a 1,278-bed, tertiary-care center affiliated with Washington University School of Medicine, St. Louis, Missouri. PARTICIPANTS: Patients admitted from January 1 to December 31, 2000. Case-patients were identified through the hospital microbiological surveillance system and matched with control-patients.
RESULTS: Predictors of candidemia included Hickman catheters (odds ratio [OR], 9.53; 95% confidence interval [CI95], 1.34 to 68.01), gastric acid suppressants (OR, 6.38; CI95, 2.33 to 17.43), nasogastric tubes (OR, 3.69; CI95, 1.27 to 10.78), antibiotics (OR, 1.46; CI95, 1.15 to 1.86), and admission to the intensive care unit (OR, 6.40; CI95, 2.12 to 19.31). The crude case-fatality rate was 40%. Seventeen (15%) of the case-patients received the recommended treatment regimen according to recently published practice guidelines.
CONCLUSIONS: The epidemiology of candidemia has changed little at our hospital during the past decade and remains a significant cause of mortality. Further studies on the benefits of preventive therapy will be essential to improve the outcome of this infection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15357152     DOI: 10.1086/502452

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  22 in total

1.  Suppression of gastric acid production by proton pump inhibitor treatment facilitates colonization of the large intestine by vancomycin-resistant Enterococcus spp. and Klebsiella pneumoniae in clindamycin-treated mice.

Authors:  Usha Stiefel; Agam Rao; Michael J Pultz; Robin L P Jump; David C Aron; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

Review 2.  Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies.

Authors:  M E Falagas; K E Apostolou; V D Pappas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-07       Impact factor: 3.267

Review 3.  Epidemiology of invasive candidiasis: a persistent public health problem.

Authors:  M A Pfaller; D J Diekema
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

4.  Candida krusei transmission among hematology patients resolved by adapted antifungal prophylaxis and infection control measures.

Authors:  Margreet C Vos; Hubert P Endtz; Deborah Horst-Kreft; Jeanette Doorduijn; Elly Lugtenburg; Henri A Verbrugh; Bob Löwenberg; Siem de Marie; Cindy van Pelt; Alex van Belkum
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

Review 5.  Epidemiology, incidence and risk factors for invasive candidiasis in high-risk patients.

Authors:  Ercole Concia; Anna Maria Azzini; Michela Conti
Journal:  Drugs       Date:  2009       Impact factor: 9.546

6.  Comparative study of the prevalence of sepsis in patients admitted to dermatology and internal medicine wards.

Authors:  Luiz Maurício Costa Almeida; Michelle dos Santos Diniz; Lorena dos Santos Diniz; Jackson Machado-Pinto; Francisco Chagas Lima Silva
Journal:  An Bras Dermatol       Date:  2013 Sep-Oct       Impact factor: 1.896

7.  Multidisciplinary approach to the treatment of invasive fungal infections in adult patients. Prophylaxis, empirical, preemptive or targeted therapy, which is the best in the different hosts?

Authors:  Rafael Zaragoza; Javier Pemán; Miguel Salavert; Angel Viudes; Amparo Solé; Isidro Jarque; Emilio Monte; Eva Romá; Emilia Cantón
Journal:  Ther Clin Risk Manag       Date:  2008-12       Impact factor: 2.423

8.  Clinical characteristics and risk factors for nosocomial candidemia in medical intensive care units: experience in a single hospital in Korea for 6.6 years.

Authors:  Seon-Sook Han; Jae-Joon Yim; Chul-Gyu Yoo; Young Whan Kim; Sung Koo Han; Young-Soo Shim; Sang-Min Lee
Journal:  J Korean Med Sci       Date:  2010-04-16       Impact factor: 2.153

9.  Candidemia on presentation to the hospital: development and validation of a risk score.

Authors:  Andrew F Shorr; Ying P Tabak; Richard S Johannes; Xiaowu Sun; James Spalding; Marin H Kollef
Journal:  Crit Care       Date:  2009-09-29       Impact factor: 9.097

10.  Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B.

Authors:  Bertrand F Dupont; Olivier Lortholary; Luis Ostrosky-Zeichner; Flavie Stucker; Vijay Yeldandi
Journal:  Crit Care       Date:  2009-10-05       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.